Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06172374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06172374 · ClinicalTrials.gov record · last posted 2025-05-11

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

StatusActive, Not Recruiting
PhaseNot specified
Started2023-08-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2023-12-07; most recent amendment 2025-05-06. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-05-06
Status change Recruiting→Active, Not Recruitingv3
Trial Details
NCT Number NCT06172374
Lead Sponsor ReCode Therapeutics
Collaborators: Sano Genetics, Reverba
Conditions Primary Ciliary Dyskinesia
Enrollment 150 participants
Start Date 2023-08-31
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-11